JPWO2021146336A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021146336A5 JPWO2021146336A5 JP2022542640A JP2022542640A JPWO2021146336A5 JP WO2021146336 A5 JPWO2021146336 A5 JP WO2021146336A5 JP 2022542640 A JP2022542640 A JP 2022542640A JP 2022542640 A JP2022542640 A JP 2022542640A JP WO2021146336 A5 JPWO2021146336 A5 JP WO2021146336A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polysorbate
- succinate
- delivery system
- drug delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012377 drug delivery Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Claims (1)
- １つまたは複数の静脈内薬物送達システム構成要素への治療的タンパク質の吸着を減らすための組成物であって、スクシネートおよびポリソルベート８０を含む、組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960602P | 2020-01-13 | 2020-01-13 | |
| US62/960,602 | 2020-01-13 | ||
| PCT/US2021/013304 WO2021146336A1 (en) | 2020-01-13 | 2021-01-13 | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512446A JP2023512446A (ja) | 2023-03-27 |
| JPWO2021146336A5 true JPWO2021146336A5 (ja) | 2024-01-23 |
Family
ID=74798008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542640A Pending JP2023512446A (ja) | 2020-01-13 | 2021-01-13 | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230151102A1 (ja) |
| EP (1) | EP4090368A1 (ja) |
| JP (1) | JP2023512446A (ja) |
| KR (1) | KR20220140500A (ja) |
| CN (1) | CN115666639A (ja) |
| AU (1) | AU2021207632A1 (ja) |
| BR (1) | BR112022013730A2 (ja) |
| CA (1) | CA3164420A1 (ja) |
| IL (1) | IL294461A (ja) |
| MX (1) | MX2022008655A (ja) |
| WO (1) | WO2021146336A1 (ja) |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| BR0014486A (pt) * | 1999-10-04 | 2002-09-17 | Chiron Corp | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado |
| PT1441589E (pt) * | 2001-11-08 | 2012-08-13 | Abbott Biotherapeutics Corp | Formulação farmacêutica líquida estável de anticorpos igg |
| ZA200506159B (en) * | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
| US7635472B2 (en) | 2003-05-31 | 2009-12-22 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| WO2004106380A2 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Human-anti-human cd3 binding molecules |
| KR101229731B1 (ko) | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| DE10348550A1 (de) * | 2003-10-20 | 2005-06-16 | Hexal Biotech Forschungsgmbh | Stabile wässrige G-CSF-haltige Zusammensetzungen |
| EP2081553B1 (en) * | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| DK2644194T3 (en) * | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| DK2356153T3 (en) | 2008-10-01 | 2016-07-04 | Amgen Res (Munich) Gmbh | Bispecific single CHAIN PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES |
| NO2344540T3 (ja) * | 2008-10-02 | 2018-04-28 | ||
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
| BR112013016153A2 (pt) * | 2010-12-22 | 2017-07-11 | Wyeth Llc | composições imunogênicas estáveis de antígenos de staphylococcus aureus |
| SG195072A1 (en) | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| EP2839019A4 (en) | 2012-04-20 | 2016-03-30 | Emergent Product Dev Seattle | CD3-BINDING POLYPEPTIDES |
| AU2015280480A1 (en) * | 2014-06-26 | 2017-01-05 | Amgen Inc. | Protein formulations |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| WO2016185016A1 (en) | 2015-05-21 | 2016-11-24 | Alligator Bioscience Ab | Novel polypeptides |
| EP3352760A4 (en) * | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3 BINDING POLYPEPTIDES |
| BR112019005333A2 (pt) * | 2016-09-21 | 2019-06-11 | Aptevo Research And Development Llc | proteínas de ligação a cd123 e composições e métodos relacionados |
| CN108261391B (zh) * | 2016-12-30 | 2022-03-01 | 江苏太平洋美诺克生物药业有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
| JP2020530554A (ja) * | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| EP3688033A4 (en) * | 2017-09-29 | 2021-06-23 | Janssen Biotech, Inc. | NEW FORMULATIONS THAT STABILIZE LOW DOSE ANTIBODY COMPOSITIONS |
-
2021
- 2021-01-13 BR BR112022013730A patent/BR112022013730A2/pt not_active Application Discontinuation
- 2021-01-13 MX MX2022008655A patent/MX2022008655A/es unknown
- 2021-01-13 IL IL294461A patent/IL294461A/en unknown
- 2021-01-13 KR KR1020227026643A patent/KR20220140500A/ko unknown
- 2021-01-13 US US17/802,927 patent/US20230151102A1/en active Pending
- 2021-01-13 CA CA3164420A patent/CA3164420A1/en active Pending
- 2021-01-13 AU AU2021207632A patent/AU2021207632A1/en active Pending
- 2021-01-13 EP EP21708781.6A patent/EP4090368A1/en active Pending
- 2021-01-13 CN CN202180020512.2A patent/CN115666639A/zh active Pending
- 2021-01-13 WO PCT/US2021/013304 patent/WO2021146336A1/en unknown
- 2021-01-13 JP JP2022542640A patent/JP2023512446A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022180461A5 (ja) | ||
| Assael et al. | Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial | |
| JP2010525050A5 (ja) | ||
| JP2016074740A5 (ja) | ||
| JP2007514749A5 (ja) | ||
| JP2007515469A5 (ja) | ||
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| ATE339954T1 (de) | Kombinationen von formoterol und tiotropium-salz | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| ES2074698T3 (es) | Composicion oral para el tratamiento de enfermedades intestinales inflamatorias. | |
| HRP20151230T1 (hr) | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 | |
| RS51304B (sr) | Farmaceutske kompozicije neuroaktivnog steroida i njihova upotreba | |
| JP2011079858A5 (ja) | ||
| HRP20180327T1 (hr) | Sredstva za uporabu u slučaju intolerancije na fruktozu | |
| AR052567A1 (es) | Combinacion de bambuterol e inhibidor de integrina | |
| Jiang et al. | Clinical application of nitric oxide in ischemia and reperfusion injury: A literature review | |
| JP2010538020A5 (ja) | ||
| AR008886A1 (es) | Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea | |
| Highsmith et al. | Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma | |
| JP2005525329A5 (ja) | ||
| JP2020536121A5 (ja) | ||
| JP2009534367A5 (ja) | ||
| JPWO2021146336A5 (ja) | ||
| JP2005508963A5 (ja) | ||
| JP2006503095A5 (ja) |